Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...
Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...
Facilities Design Services supports the UTA community in planning, designing and implementing interior environments. As stewards of our campus’ building heritage, we bring both a long-range and ...
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback